429 related articles for article (PubMed ID: 15892677)
1. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome.
Barbaro G; Scozzafava A; Mastrolorenzo A; Supuran CT
Curr Pharm Des; 2005; 11(14):1805-43. PubMed ID: 15892677
[TBL] [Abstract][Full Text] [Related]
2. New advances in HIV entry inhibitors development.
Rusconi S; Scozzafava A; Mastrolorenzo A; Supuran CT
Curr Drug Targets Infect Disord; 2004 Dec; 4(4):339-55. PubMed ID: 15578975
[TBL] [Abstract][Full Text] [Related]
3. An update in the development of HIV entry inhibitors.
Rusconi S; Scozzafava A; Mastrolorenzo A; Supuran CT
Curr Top Med Chem; 2007; 7(13):1273-89. PubMed ID: 17627557
[TBL] [Abstract][Full Text] [Related]
4. New developments in anti-HIV chemotherapy.
De Clercq E
Curr Med Chem; 2001 Nov; 8(13):1543-72. PubMed ID: 11562282
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors.
Mastrolorenzo A; Rusconi S; Scozzafava A; Barbaro G; Supuran CT
Curr Med Chem; 2007; 14(26):2734-48. PubMed ID: 18045120
[TBL] [Abstract][Full Text] [Related]
6. Emerging drug targets for antiretroviral therapy.
Reeves JD; Piefer AJ
Drugs; 2005; 65(13):1747-66. PubMed ID: 16114975
[TBL] [Abstract][Full Text] [Related]
7. New anti-HIV agents and targets.
De Clercq E
Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
[TBL] [Abstract][Full Text] [Related]
8. New developments in anti-HIV chemotherapy.
De Clercq E
Biochim Biophys Acta; 2002 Jul; 1587(2-3):258-75. PubMed ID: 12084468
[TBL] [Abstract][Full Text] [Related]
9. HIV co-receptors as targets for antiviral therapy.
Schols D
Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
De Clercq E; Schols D
Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
[TBL] [Abstract][Full Text] [Related]
11. Novel compounds in preclinical/early clinical development for the treatment of HIV infections.
De Clercq E
Rev Med Virol; 2000; 10(4):255-77. PubMed ID: 10891872
[TBL] [Abstract][Full Text] [Related]
12. HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches.
De Clercq E
Int J Biochem Cell Biol; 2004 Sep; 36(9):1800-22. PubMed ID: 15183346
[TBL] [Abstract][Full Text] [Related]
13. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
14. The development of anti-HIV-1 drugs.
Lu XF; Chen ZW
Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
[TBL] [Abstract][Full Text] [Related]
15. Emerging anti-HIV drugs.
De Clercq E
Expert Opin Emerg Drugs; 2005 May; 10(2):241-73. PubMed ID: 15934866
[TBL] [Abstract][Full Text] [Related]
16. New antiretroviral drugs.
Gulick RM
Clin Microbiol Infect; 2003 Mar; 9(3):186-93. PubMed ID: 12667250
[TBL] [Abstract][Full Text] [Related]
17. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
Hughes A; Barber T; Nelson M
J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070
[TBL] [Abstract][Full Text] [Related]
18. HIV entry and fusion inhibitors.
Chantry D
Expert Opin Emerg Drugs; 2004 May; 9(1):1-7. PubMed ID: 15155132
[TBL] [Abstract][Full Text] [Related]
19. The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets.
Turpin JA
Expert Rev Anti Infect Ther; 2003 Jun; 1(1):97-128. PubMed ID: 15482105
[TBL] [Abstract][Full Text] [Related]
20. Simple and general criterion for "in silico" screening of candidate HIV drugs.
Veljkovic N; Glisic S; Prljic J; Perovic V; Veljkovic V
Curr Pharm Biotechnol; 2013; 14(5):561-9. PubMed ID: 22429138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
